Doceree has launched Clinical Intent Signals (CIS), a new data layer designed to detect and activate real-time “clinical intent” signals across omnichannel healthcare marketing. The product is slated to be available through Doceree’s Daily Command Marketplace when Daily Command debuts publicly on July 14, 2026.
The announcement matters because healthcare marketers have historically relied on lagging indicators (such as prescribing and claims patterns) and static segmentation. CIS is positioned as a way to trigger messaging and channel decisions closer to the clinical workflow moments that precede prescribing behavior, while staying within privacy-first and PHI-compliant constraints.
Table of contents
Jump to each section:
- What Clinical Intent Signals is and what it changes
- How CIS fits into omnichannel execution and martech stacks
- Pilot metrics and what they suggest (and don’t)
- Competitive landscape in healthcare AdTech
- Why “intent layers” are showing up now in healthcare marketing
- Operational considerations for life sciences marketers
ContentGrip
What Clinical Intent Signals is and what it changes
CIS is framed as an intelligence layer that translates “digital exhaust” from clinical decision-making into activatable intent stages. In practical terms, that includes behaviors like guideline lookups, peer content consumption, journal reading patterns, and workflow signals across environments used by healthcare professionals (HCPs), such as EHR-adjacent and point-of-care contexts.
The key shift is moving from retrospective measurement (what happened after a prescribing change appears in data) to earlier engagement triggers (what an HCP appears to be researching and considering now). If the signal quality is consistent, this could change how life sciences teams time messages, sequence channels, and decide when to suppress or expand audiences.
How CIS fits into omnichannel execution and martech stacks
Doceree is positioning CIS as a unifying signal that can be used across paid media, email, rep triggers, and content workflows, with integrations and connectors distributed via the Daily Command Marketplace and an open API. For marketers, the realistic value is less about a new dashboard and more about reducing “signal fragmentation”, where different vendors and channels optimize to different definitions of engagement and readiness.
If CIS is adopted as a shared input, it can function like a common decisioning layer that informs:
- creative and message alignment based on stage, not just specialty or historic prescribing
- frequency and channel allocation based on observed context shifts
- suppression rules when intent signals indicate a clinician has moved past a decision stage (or is no longer active)
This is also where implementation risk sits. Any “intent layer” only works if downstream systems can actually act on it (DSP configurations, CRM logic, field enablement triggers, and MLR-approved content mapping).
Pilot metrics and what they suggest (and don’t)
Doceree cites a 12-week pilot across 36,000 matched HCPs spanning multiple therapeutic areas, reporting:
- 38% faster stage progression through the HCP decision journey
- 27% higher contextual engagement versus matched control cohorts
- 21% improvement in media efficiency (based on blended cost-per-qualified-engagement benchmarks)
These results, if repeatable, point to a potential efficiency case: earlier identification of “in-market” clinical research behavior could reduce wasted impressions and improve sequencing across channels. At the same time, marketers should treat pilot numbers as directional until they understand definitions (how “stage progression” is operationalized), cohort construction, and whether lift holds across therapy areas with different data availability and decision cycles.
Competitive landscape in healthcare AdTech
Healthcare-focused AdTech is a crowded category built around compliant access to HCP audiences, point-of-care inventory, and measurable engagement. Doceree competes in a landscape that includes players such as DeepIntent, BulletinHealthcare, and Mktg.Doctor, where differentiation often comes down to (1) data access and fidelity, (2) activation breadth across channels, and (3) governance and compliance confidence for regulated brands.
CIS is an attempt to compete on the “signal layer” rather than just inventory access. If Doceree can standardize intent stages that work across multiple activation endpoints, it may reduce the need for channel-specific proxies for readiness. Competitors with strong reach and publisher/EHR adjacency may counter by emphasizing scale, proprietary point-of-care contexts, or established measurement frameworks.
Why “intent layers” are showing up now in healthcare marketing
In B2B marketing, intent data has been used for years to prioritize accounts and trigger outreach. Healthcare has been slower because clinical data is fragmented and more tightly governed. CIS reflects a broader push toward AI-supported marketing workflow automation, where systems attempt to infer decision context and route actions automatically rather than relying on quarterly segmentation refreshes.
The more automation expands, the more teams need a defensible input signal that aligns stakeholders across brand, omnichannel, analytics, and field teams. An “intent layer” is one way to create that shared language, provided it is transparent enough to be trusted and auditable enough to fit regulated operating models.
Operational considerations for life sciences marketers
For teams evaluating CIS or similar offerings, a few practical questions will determine impact:
- Signal governance: What is the source coverage across EHR/point-of-care/journals, and how are signals validated at the HCP level without drifting into patient-level sensitivity?
- MLR fit: How are stages mapped to MLR-approved content and claims boundaries, and what controls exist for real-time personalization?
- Measurement alignment: How will “qualified engagement” and downstream outcomes be defined so media, brand, and field teams do not optimize to conflicting KPIs?
- Activation readiness: Are DSP, CRM, and rep tools configured to consume stage updates quickly enough to matter, or will “real-time” degrade into batch workflows?
- Therapy-area variability: Do signals perform consistently in specialties with less digital exhaust or different guideline usage patterns?
If the plumbing is not in place, intent data can become another dashboard. If it is, it can become an operational input that changes how budgets and sequences are set week-to-week instead of quarter-to-quarter.
Leave a Reply